NASDAQ:CMPS COMPASS Pathways (CMPS) Stock Price, News & Analysis $2.72 -0.15 (-5.07%) As of 02:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About COMPASS Pathways Stock (NASDAQ:CMPS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get COMPASS Pathways alerts:Sign Up Key Stats Today's Range$2.73▼$2.8650-Day Range$2.86▼$4.9952-Week Range$2.72▼$10.31Volume496,671 shsAverage Volume1.19 million shsMarket Capitalization$251.61 millionP/E RatioN/ADividend YieldN/APrice Target$20.20Consensus RatingBuy Company OverviewCOMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Read More… Remove Ads COMPASS Pathways Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreCMPS MarketRank™: COMPASS Pathways scored higher than 67% of companies evaluated by MarketBeat, and ranked 336th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingCOMPASS Pathways has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCOMPASS Pathways has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about COMPASS Pathways' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for COMPASS Pathways are expected to grow in the coming year, from ($2.33) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of COMPASS Pathways is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of COMPASS Pathways is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCOMPASS Pathways has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about COMPASS Pathways' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.61% of the float of COMPASS Pathways has been sold short.Short Interest Ratio / Days to CoverCOMPASS Pathways has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in COMPASS Pathways has recently decreased by 8.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCOMPASS Pathways does not currently pay a dividend.Dividend GrowthCOMPASS Pathways does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.61% of the float of COMPASS Pathways has been sold short.Short Interest Ratio / Days to CoverCOMPASS Pathways has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in COMPASS Pathways has recently decreased by 8.59%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News Sentiment0.68 News SentimentCOMPASS Pathways has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for COMPASS Pathways this week, compared to 2 articles on an average week.Search InterestOnly 12 people have searched for CMPS on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added COMPASS Pathways to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, COMPASS Pathways insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.25% of the stock of COMPASS Pathways is held by insiders.Percentage Held by Institutions46.19% of the stock of COMPASS Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about COMPASS Pathways' insider trading history. Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPS Stock News HeadlinesCOMPASS Pathways' (CMPS) Overweight Rating Reiterated at Cantor FitzgeraldMarch 30 at 2:14 AM | americanbankingnews.comThis Is a Test From GlobeNewswireMarch 28, 2025 | globenewswire.comIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”... “The future of AI”... And “a revolutionary leap forward.” Tech legend and angel investor Jeff Brown believes this AI is so powerful that it will kill ChatGPT… And make a lot of people rich in the process.April 1, 2025 | Brownstone Research (Ad)Compass Pathways announces published study on psilocybin in depressionMarch 18, 2025 | markets.businessinsider.comCompass one of the most compelling stories in neuropsych, says H.C. WainwrightMarch 4, 2025 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Ramsay Health Care (OtherRMSYF) and COMPASS Pathways (CMPS)March 3, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Rani Therapeutics Holdings (RANI)March 1, 2025 | markets.businessinsider.comCOMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025March 1, 2025 | msn.comSee More Headlines CMPS Stock Analysis - Frequently Asked Questions How have CMPS shares performed this year? COMPASS Pathways' stock was trading at $3.78 at the beginning of the year. Since then, CMPS stock has decreased by 26.9% and is now trading at $2.7650. View the best growth stocks for 2025 here. How were COMPASS Pathways' earnings last quarter? COMPASS Pathways plc (NASDAQ:CMPS) posted its earnings results on Thursday, February, 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.01. When did COMPASS Pathways IPO? COMPASS Pathways (CMPS) raised $100 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 6,700,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg served as the underwriters for the IPO and Canaccord Genuity was co-manager. How do I buy shares of COMPASS Pathways? Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of COMPASS Pathways own? Based on aggregate information from My MarketBeat watchlists, some other companies that COMPASS Pathways investors own include Symbotic (SYM), Enovix (ENVX), Rambus (RMBS), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA). Company Calendar Last Earnings2/27/2025Today4/01/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMPS CIK1816590 Webwww.compasspathways.com Phone716-676-6461FaxN/AEmployees120Year Founded2016Price Target and Rating Average Stock Price Target$20.20 High Stock Price Target$45.00 Low Stock Price Target$11.00 Potential Upside/Downside+606.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-63.85% Return on Assets-51.97% Debt Debt-to-Equity Ratio0.15 Current Ratio8.91 Quick Ratio8.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.65 per share Price / Book0.78Miscellaneous Outstanding Shares92,673,000Free Float65,513,000Market Cap$265.04 million OptionableOptionable Beta2.29 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:CMPS) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredNew Pick (93% history of rising by May 8)We just posted a new recommendation. Keep in mind: You could have boosted the Netflix trade we issued to the p...InvestorPlace | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways plc Please log in to your account or sign up in order to add this asset to your watchlist. Share COMPASS Pathways With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.